CFO
TXG icon

CVA Family Office’s 10x Genomics TXG Stock Holding History

CVA Family Office’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$192 Hold
5
– – ﹤0.01% 1771
2026
Q1 		$106 Hold
5
– – ﹤0.01% 1822
2025
Q4 		$82 Hold
5
– – ﹤0.01% 1281
2025
Q3 		$58 Hold
5
– – ﹤0.01% 1293
2025
Q2 		$58 Hold
5
– – ﹤0.01% 1275
2025
Q1 		$44 Hold
5
– – ﹤0.01% 1383
2024
Q4 		$72 Sell
5
-33
-87% -$521 ﹤0.01% 1278
2024
Q3 		$858 Buy
38
+15
+65% +$310 ﹤0.01% 1094
2024
Q2 		$447 Buy
+23
New +$602 ﹤0.01% 1246

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CVA Family Office's TXG Position: Q2 2026 in Review

CVA Family Office held its 10x Genomics (TXG) position steady in Q2 2026 at 5 shares worth $192. The position accounts for ﹤0.01% of the portfolio, ranked #1771.

CVA Family Office first reported a position in TXG in Q2 2024 and has held it in 9 quarters since. The position peaked at $858 in Q3 2024. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • CVA Family Office held 5 shares of 10x Genomics worth $192 as of Q2 2026.
  • CVA Family Office left its 10x Genomics share count unchanged in Q2 2026.
  • 10x Genomics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1771 holding.
  • CVA Family Office first reported a position in 10x Genomics in Q2 2024 and has held it in 9 quarters since.
  • CVA Family Office's 10x Genomics position peaked at $858 in Q3 2024.
  • 392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.